UK markets close in 3 hours 23 minutes

Zealand Pharma A/S (ZLDPF)

Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
18.010.00 (0.00%)
At close: 03:46PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close18.01
Open17.84
BidN/A x N/A
AskN/A x N/A
Day's range18.01 - 18.01
52-week range11.14 - 31.65
Volume200
Avg. volume134
Market cap782.779M
Beta (5Y monthly)1.34
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Globe Newswire

    Zealand Pharma Announces Oral Presentation of Phase 2 Data for BI 456906 at the 58th Annual Meeting of the European Association for the Study of Diabetes (EASD)

    Press release – No. 6 / 2022 Zealand Pharma Announces Oral Presentation of Phase 2 Data for BI 456906 at the 58th Annual Meeting of the European Association for the Study of Diabetes (EASD) BI 456906 effectively lowered HbA1c up to -1.88% at week 16 in patients with type 2 diabetes in the Phase 2 clinical trialPreclinical pharmacology of BI 456906 supports ongoing Phase 2 studies in obesity or non-alcoholic steatohepatitis Copenhagen, Denmark and Boston MA, U.S. September 21, 2022 – Zealand Phar

  • Globe Newswire

    Zealand Pharma Presents Data from Phase 3 Trial of Dasiglucagon in Congenital Hyperinsulinism at the 60th Annual ESPE Meeting

    Press release – No. 5 / 2022 Zealand Pharma Presents Data from Phase 3 Trial of Dasiglucagon in Congenital Hyperinsulinism at the 60th Annual ESPE Meeting Dasiglucagon significantly reduced the requirement for intravenous glucose to maintain glycemia in newborns and infants with CHI (Part 1 of Phase 3 trial)Dasiglucagon reduced time in hypoglycemia and enabled discontinuation of intravenous glucose in most infants and limited the need for pancreatectomy (Part 2 of Phase 3 trial)Results support t

  • Globe Newswire

    Zealand Pharma grants warrants to employees in Denmark

    Company announcement – No. 40 / 2022 Zealand Pharma grants warrants to employees in Denmark Copenhagen, DK and Boston, MA, September 13, 2022 – Zealand Pharma A/S (“Zealand”) (Nasdaq: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, announces granting of warrants to employees in accordance with Zealand's Remuneration policy and overall guidelines for incentive pay, as adopted at the annual genera